Shares of ProMetic Life Sciences Inc. (TSE:PLI) have received a consensus rating of “Buy” from the five analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is C$3.60.

PLI has been the subject of a number of research analyst reports. National Bank Financial raised their price objective on ProMetic Life Sciences from C$2.00 to C$2.50 in a research report on Wednesday, August 30th. Scotiabank cut their price objective on ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating for the company in a research report on Friday, July 7th. Royal Bank Of Canada cut their price objective on ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating for the company in a research report on Wednesday, August 16th. Finally, TD Securities cut their price objective on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a research report on Wednesday, August 16th.

In other ProMetic Life Sciences news, insider Bruce Pritchard purchased 48,400 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The stock was purchased at an average price of C$1.30 per share, with a total value of C$62,920.00. Also, insider Jonathan Booth purchased 75,000 shares of the stock in a transaction that occurred on Friday, October 6th. The stock was acquired at an average cost of C$1.21 per share, with a total value of C$90,750.00. In the last ninety days, insiders purchased 184,150 shares of company stock valued at $231,429 and sold 388,397 shares valued at $507,577.

Shares of ProMetic Life Sciences (TSE PLI) traded up 1.87% during midday trading on Thursday, reaching $1.63. The company’s stock had a trading volume of 522,897 shares. The company’s 50-day moving average price is $1.53 and its 200-day moving average price is $1.74. ProMetic Life Sciences has a 12 month low of $1.12 and a 12 month high of $3.24. The company’s market cap is $1.15 billion.

WARNING: This news story was first reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/19/prometic-life-sciences-inc-pli-receives-average-rating-of-buy-from-analysts.html.

About ProMetic Life Sciences

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.